<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24291" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Linezolid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Azzouz</surname>
            <given-names>Angela</given-names>
          </name>
          <aff>Henry Ford Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angela Azzouz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24291.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Linezolid is a synthetic oxazolidinone antimicrobial drug indicated for gram-positive infections and approved for the treatment of bacterial pneumonia, skin and skin structure infections, and vancomycin-resistant enterococcal (VRE) infections, including infections complicated by bacteremia. Linezolid does not have approval for the treatment of gram-negative infections, catheter-related bloodstream infections, or catheter site infections.&#x000a0;The primary mechanism of linezolid is an alternative to vancomycin in inpatient settings. This activity covers linezolid so that interprofessional team members can recognize its indications, coverage, contraindications, and adverse event profile to optimally manage patients with infectious diseases and exercise appropriate antimicrobial stewardship.&#x000a0;</p>
        <p>Empowering healthcare professionals with enhanced proficiency is pivotal in advancing patient care standards, particularly in the dynamic landscape of bacterial infection management, where pathogens like methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) present formidable challenges.&#x000a0;Participating clinicians are equipped with the&#x000a0;skills to effectively integrate linezolid into clinical practice, ensuring optimal treatment outcomes&#x000a0;when treating bacterial infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the mechanism of action for linezolid to apply knowledge of the spectrum of activity against pathogens.</p></list-item><list-item><p>Determine&#x000a0;the indications for initiating linezolid therapy by considering clinical presentation, medication interactions, and risk factors.</p></list-item><list-item><p>Evaluate bacterial infections&#x000a0;with infectious disease&#x000a0;consultation&#x000a0;to optimize&#x000a0;the use of linezolid in patient treatment plans.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve treatment efficacy from&#x000a0;linezolid therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24291">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24291.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Linezolid is a synthetic oxazolidinone antimicrobial drug. Linezolid is indicated for gram-positive infections and is approved for treating skin and skin structure infections, bacterial pneumonia, and vancomycin-resistant enterococcal (VRE) infections, including infections complicated by bacteremia. Linezolid is not approved for treating gram-negative infections, catheter-related bloodstream infections, or catheter site infections. Vancomycin&#x000a0;is a standard treatment for methicillin-resistant&#x000a0;<italic toggle="yes">Staphylococcus aureus&#x000a0;</italic>(MRSA) infection. However, vancomycin-resistant isolates of&#x000a0;<italic toggle="yes">S</italic>&#x000a0;<italic toggle="yes">aureus&#x000a0;</italic>have emerged, and increasing reports of vancomycin-resistant isolates are available worldwide, making linezolid a valuable agent in chemotherapeutics.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enterococcal infections (vancomycin-resistant): The VRE bacteremia is a growing nosocomial infection with limited treatment options, leading to significant mortality, prolonged hospital stays, and increased healthcare costs.&#x000a0;The primary function of linezolid&#x000a0;is for vancomycin-resistant <italic toggle="yes">E</italic><italic toggle="yes">nterococcus</italic>&#x000a0;<italic toggle="yes">faecium&#x000a0;</italic>infections. The Infectious Diseases Society of America (IDSA) states that linezolid or daptomycin&#x000a0;are potential treatment options for infections caused by VRE.<xref ref-type="bibr" rid="article-24291.r1">[1]</xref>&#x000a0;Inappropriate use of these antibiotics has increased linezolid and vancomycin-resistant enterococci.<xref ref-type="bibr" rid="article-24291.r2">[2]</xref><xref ref-type="bibr" rid="article-24291.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pneumonia: The IDSA and the American Thoracic Society (ATS) recommend the use of vancomycin or linezolid for the treatment of MRSA-associated hospital-acquired pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). In the decision-making process between vancomycin and linezolid for MRSA-associated HAP/VAP treatment, it is recommended that clinicians consider patient-specific factors such as concurrent use of serotonin-reuptake inhibitors and renal function to guide their selection of antibiotics.<xref ref-type="bibr" rid="article-24291.r4">[4]</xref>&#x000a0;For community-acquired pneumonia, consider linezolid only if severe pneumonia with MRSA/VRSA is suspected.<xref ref-type="bibr" rid="article-24291.r5">[5]</xref>&#x000a0;An analysis of the antibiotic susceptibility from the cases reviewed indicates that vancomycin-resistant<italic toggle="yes">&#x000a0;Staphylococcus aureus</italic>&#x000a0;(VRSA) infections were most susceptible to linezolid. Similarly, vancomycin-intermediate&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;(VISA) infections were most susceptible to quinupristin/dalfopristin. However, as recommended by the CDC, susceptibility testing is extremely important for a focused treatment plan.<xref ref-type="bibr" rid="article-24291.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin and soft tissue infections (SSTI): Linezolid can be used for MRSA infections in hospitalized adults with complicated skin and soft tissue infection, community-associated MRSA skin and soft tissue infection, and MRSA-associated purulent and nonpurulent cellulitis. Linezolid is also an alternative option for MRSA in hospitalized pediatric patients. However, linezolid is not FDA-approved for treating SSTI associated with osteomyelitis. According to the IDSA, empiric administration of vancomycin or other antibiotics with gram-positive activity, such as linezolid, daptomycin, or ceftaroline, should be considered for patients with recurrent or persistent fever and neutropenia.<xref ref-type="bibr" rid="article-24291.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-FDA uses include anthrax, bone and joint infections, brain abscess, febrile neutropenia, infectious arthritis, meningitis, orthopedic device-related infection, osteomyelitis, sepsis, subdural empyema, and ventriculitis. The use of linezolid in anthrax is endorsed by the CDC guidelines, especially in patients with systemic disease and possible meningitis due to excellent central nervous system (CNS) penetration.<xref ref-type="bibr" rid="article-24291.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Linezolid has demonstrated activity against most strains of the following microorganisms:&#x000a0;<italic toggle="yes">Enterococcus faecalis, Enterococcus faecium</italic>,&#x000a0;<italic toggle="yes">Pasteurella multiocida</italic>,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;(MRSA and MSSA, ie, methicillin-sensitive),&#x000a0;<italic toggle="yes">Staphylococcus epidermidis</italic>,&#x000a0;<italic toggle="yes">Staphylococcus haemolyticus</italic>,&#x000a0;<italic toggle="yes">Streptococcus agalactiae&#x000a0;</italic>(group B streptococci),&#x000a0;<italic toggle="yes">Streptococcus pneumonia</italic>,&#x000a0;<italic toggle="yes">Streptococcus pyogenes&#x000a0;</italic>(group A beta-hemolytic streptococci), and viridians group streptococci<italic toggle="yes">&#x000a0;(S mutans, S salivarius, S anginosus, S mitis, S sanguinis, and S bovis).</italic><xref ref-type="bibr" rid="article-24291.r9">[9]</xref><xref ref-type="bibr" rid="article-24291.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24291.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Linezolid is the first approved oxazolidinone to inhibit bacterial protein synthesis by interfering with translation. Linezolid attaches to a site on the bacterial 23S ribosomal RNA of the 50S subunit, preventing the formation of a functional 70S initiation complex.<xref ref-type="bibr" rid="article-24291.r11">[11]</xref>&#x000a0;This activity essentially inhibits protein production and prevents bacteria from multiplying.&#x000a0;Linezolid is bacteriocidal against most streptococcal strains and bacteriostatic against staphylococci and enterococci; this makes linezolid a poor option for immunosuppressed patients.</p>
        <p>Linezolid is also a reversible, nonselective monoamine oxidase (MAO) inhibitor.<xref ref-type="bibr" rid="article-24291.r12">[12]</xref>&#x000a0;Monoamine oxidase inhibition leads to an increased concentration of the neurotransmitters epinephrine, norepinephrine, dopamine, and serotonin in the central and sympathetic nervous system. Inhibition can also desensitize alpha- and beta-adrenergic and serotonin receptors. Inhibition of MAO in the gastrointestinal tract and liver can lead to absorption of high levels of tyramine from the diet, which may cause life-threatening hypertension.</p>
        <p>Resistance in MRSA is due to a point mutation in the 23S rRNA.<xref ref-type="bibr" rid="article-24291.r13">[13]</xref>&#x000a0;Additionally, linezolid resistance in staphylococci can be attributed to a methyltransferase enzyme. This type of resistance is governed by the CFR (chloramphenicol-florfenicol) gene, which resides on a plasmid and can be transferred between staphylococcal bacteria.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Linezolid is well absorbed after oral dosing with an absolute bioavailability of approximately 100%.&#x000a0;The drug can be administered orally or intravenously without dose adjustment and can be administered with or without food (food delays the rate but not the extent of oral absorption).<xref ref-type="bibr" rid="article-24291.r14">[14]</xref></p>
        <p><bold>Distribution:</bold> Linezolid readily distributes to well-perfused tissues, with a plasma protein binding of about 31%. The volume of distribution (Vd) at steady-state in healthy adults is approximately 40 to 50 liters. Linezolid crosses the blood-brain barrier, making it a valuable option for CNS infections caused by MRSA.<xref ref-type="bibr" rid="article-24291.r15">[15]</xref>&#x000a0;The study found that despite lower linezolid concentrations in the lung compared to serum, these concentrations remained above the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) values in almost all patients with drug-resistant tuberculosis.<xref ref-type="bibr" rid="article-24291.r16">[16]</xref></p>
        <p><bold>Metabolism:</bold> Linezolid undergoes oxidation of the morpholine ring, resulting in&#x000a0;2 inactive carboxylic acid metabolites (A and B). Metabolite A is formed enzymatically, while metabolite B is produced via a non-enzymatic chemical oxidation mechanism.</p>
        <p><bold>Excretion:</bold> Renal clearance is about 40 mL/min, indicating tubular reabsorption. Under steady-state conditions, approximately 30% of the administered dose is eliminated in the urine as linezolid, while 40% and 10% are excreted as metabolite B and metabolite A. Metabolites of linezolid can accumulate in patients with renal impairment.<xref ref-type="bibr" rid="article-24291.r17">[17]</xref></p>
      </sec>
      <sec id="article-24291.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Linezolid is available in tablets, suspension, and injection. The dosage of intravenous (IV) and tablet formulations are interchangeable. Renal dosing is not required. Invert gently to mix before administration, and do not vigorously shake the oral suspension. Linezolid is available as an injectable solution at a concentration of 2 mg/mL, an oral suspension of 100 mg/5 mL, and tablets containing 600 mg.</p>
        <p>Administer linezolid IV infusion over 30 to 120 minutes. Do not mix or infuse with other medications. When using the same IV line for sequential infusion, flush the line with D5W, normal saline, or lactated Ringer's solution before and after infusing linezolid. The yellow color of the injection may intensify with time without affecting potency. Linezolid use may result in a suboptimal clinical response when treating organisms with a MIC (minimum inhibitory concentration) of 4 mcg/ml or greater and warrants a complete&#x000a0;infectious disease&#x000a0;re-assessment and change in drug therapy.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Nosocomial pneumonia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose for nosocomial pneumonia is 600 mg, administered&#x000a0;IV or orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment is typically continued for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Community-acquired pneumonia with concurrent bacteremia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose of community-acquired pneumonia with concurrent bacteremia is 600 mg administered&#x000a0;IV or orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment usually continues for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Complicated skin and skin structure infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: In complicated skin and soft tissue infections (cSSTIs), the recommended linezolid dosage is 600 mg&#x000a0;IV or orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment typically is for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Uncomplicated skin and skin structure infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: Adults should take a dose of 400 mg orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment typically is for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Vancomycin-resistant<italic toggle="yes">&#x000a0;Enterococcus faecium</italic>&#x000a0;infections, including concurrent bacteremia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose for vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic> infections, including concurrent bacteremia, is 600 mg administered&#x000a0;IV or orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment is extended for a period of 14 to 28 days.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment</bold>: Linezolid pharmacokinetics remain unchanged in mild-to-moderate hepatic impairment (Child-Pugh class A or B), and no dosage adjustment is recommended. The risk of hematological toxicity increases in patients with cirrhosis.<xref ref-type="bibr" rid="article-24291.r18">[18]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Use linezolid with caution in renal impairment due to the risk of thrombocytopenia.<xref ref-type="bibr" rid="article-24291.r19">[19]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Linezolid is excreted into breast milk at concentrations likely to be effective against staphylococcal strains commonly found in mastitis. Limited clinical data suggest that infants would receive 6% to 9% of the standard infant dose through breast milk; thus, monitoring the infant for potential gastrointestinal effects, such as diarrhea and vomiting, is advisable. Due to limited published experience with linezolid during breastfeeding, an alternative drug may be preferred, especially when nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-24291.r20">[20]</xref>&#x000a0;</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;A lack of pharmacokinetic and controlled studies of linezolid are available in pregnant women. A case report demonstrated positive maternal outcomes without fetal teratogenesis during a 4-week course of linezolid initiated at the 14th week of pregnancy. Linezolid could be used during pregnancy when the potential benefits outweigh the risks.<xref ref-type="bibr" rid="article-24291.r21">[21]</xref>&#x000a0;Linezolid has also been used in pregnancy for multidrug resistant tuberculosis (MDR-TB); however, clinicians should monitor for adverse effects.<xref ref-type="bibr" rid="article-24291.r22">[22]</xref>&#x000a0;Animal studies indicate that higher doses in mice resulted in maternal toxicity, increased embryo death, and decreased fetal body weights, with costal cartilage fusion. Reduced fetal body weights and decreased ossification of sternebrae at the higher dose were seen in rats.</p>
        <p>
<bold>Pediatric patients</bold>
</p>
        <p>
<bold>Nosocomial pneumonia:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose for nosocomial pneumonia is 10 mg/kg&#x000a0;IV or orally every 8 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment is typically continued for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Community-acquired pneumonia with concurrent bacteremia:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose for community-acquired pneumonia with concurrent bacteremia is 10 mg/kg&#x000a0;IV or orally every 8 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment usually continues for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Complicated skin and skin structure infections:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: In complicated skin and soft tissue infections (cSSTIs), the linezolid dosage is 10 mg/kg IV or orally every 8 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment typically is for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Uncomplicated skin and skin structure infections:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: For uncomplicated skin and skin structure infections, children aged less than&#x000a0;5&#x000a0;should be prescribed 10 mg/kg orally every 8 hours. Children aged 5 to 11 should be prescribed 10 mg/kg orally every 12 hours.</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment typically is for 10 to 14 days.</p>
          </list-item>
        </list>
        <p>
<bold>Vancomycin-resistant<italic toggle="yes">&#x000a0;Enterococcus faecium</italic>&#x000a0;infections, including concurrent bacteremia:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose: The recommended dose for vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic> infections, including concurrent bacteremia, is 10 mg/kg&#x000a0;IV or orally every 8 hours</p>
          </list-item>
          <list-item>
            <p>Duration: Treatment is extended for a period of 14 to 28 days.</p>
          </list-item>
        </list>
        <p><bold>Older patients:</bold>&#x000a0;Clinical studies did not reveal significant disparities in the safety or effectiveness of linezolid between older and younger patients. However, increased sensitivity to linezolid in older patients is possible.</p>
      </sec>
      <sec id="article-24291.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects experienced with linezolid use include decreased platelets, hemoglobin, white blood cell counts, headache, nausea, diarrhea, elevated pancreatic enzymes, elevated liver function tests, and neuropathy.<xref ref-type="bibr" rid="article-24291.r23">[23]</xref><xref ref-type="bibr" rid="article-24291.r24">[24]</xref>&#x000a0;Warnings associated with linezolid include duration-related myelosuppression (thrombocytopenia, anemia, leukopenia), serotonin syndrome, hypoglycemia; caution in patients on insulin or hypoglycemic drugs, seizures, lactic acidosis, hypertension when used with adrenergic drugs, and irreversible peripheral and optic neuropathy when used for 28 days or greater. Reports exist of blurred vision in patients receiving shorter courses of linezolid.<xref ref-type="bibr" rid="article-24291.r8">[8]</xref>&#x000a0;Prolonged use may result in fungal or bacterial infection, including&#x000a0;<italic toggle="yes">Clostridioides difficile</italic>-associated diarrhea (CDAD) and pseudomembranous colitis. CDAD can occur greater than&#x000a0;2 months after postantibiotic treatment. Lactic acidosis may also occur with use; evaluate patients who develop recurrent nausea and vomiting, unexplained acidosis, or low bicarbonate concentrations.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Adrenergic drugs:</bold> Avoid using linezolid with adrenergic drugs such as pseudoephedrine, epinephrine, norepinephrine, dopamine, or dobutamine due to the risk of hypertensive crisis.</p>
        <p><bold>Serotonergic drugs:</bold> Serotonin syndrome can occur when linezolid is co-administered with serotonergic agents such as SSRI.&#x000a0;Therefore, linezolid should not be used with patients taking serotonergic antidepressants or other medications like tricyclic antidepressants, bupropion, buspirone, triptans, or meperidine unless clinically necessary and closely monitored for signs of serotonin syndrome or neuroleptic malignant syndrome. If urgent linezolid treatment is required for patients already taking serotonergic drugs, discontinue the antidepressant and administer linezolid. Monitor for&#x000a0;2 weeks and up to&#x000a0;5 weeks with fluvoxamine.<xref ref-type="bibr" rid="article-24291.r25">[25]</xref></p>
        <p><bold>Myelosuppressive agents:</bold> Linezolid should be cautiously used with drugs that can cause bone marrow suppression. Concurrent administration of linezolid with drugs such as clozapine and cladribine should be avoided.<xref ref-type="bibr" rid="article-24291.r26">[26]</xref><xref ref-type="bibr" rid="article-24291.r27">[27]</xref><xref ref-type="bibr" rid="article-24291.r28">[28]</xref><xref ref-type="bibr" rid="article-24291.r29">[29]</xref><xref ref-type="bibr" rid="article-24291.r30">[30]</xref></p>
      </sec>
      <sec id="article-24291.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Linezolid administration is contraindicated in individuals with a documented hypersensitivity to the drug or its excipients. Anaphylactoid reactions have been reported.&#x000a0;Do not use within&#x000a0;2 weeks of MAO inhibitors like phenelzine.<xref ref-type="bibr" rid="article-24291.r31">[31]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Myelosuppression:</bold> Weekly monitoring of complete blood counts is advisable. Thrombocytopenia is more frequently reported in patients with renal impairment and hepatic impairment. Consider discontinuation of linezolid if evidence of myelosuppression is apparent.<xref ref-type="bibr" rid="article-24291.r19">[19]</xref>&#x000a0;Use caution with serotonergic and adrenergic drugs, eg, imipramine.<xref ref-type="bibr" rid="article-24291.r32">[32]</xref></p>
        <p><bold>Peripheral neuropathy and optic neuropathy:</bold> Cases have been documented in patients receiving treatment over 28 days. Prompt ophthalmic evaluation is recommended if patients experience visual impairment symptoms. A study identified a correlation between higher doses of linezolid and reduced rates of full recovery in patients, indicating a dose-dependent aspect of linezolid-induced optic neuropathy.<xref ref-type="bibr" rid="article-24291.r33">[33]</xref></p>
        <p><bold>Serotonin syndrome:</bold> Patients&#x000a0;prescribed serotonergic agents, including antidepressants, should be closely observed for signs of serotonin syndrome. Linezolid should be administered to patients taking serotonergic antidepressants only when no alternative therapies are available. Discontinue serotonergic antidepressants and monitor for signs of serotonin syndrome and antidepressant discontinuation.<xref ref-type="bibr" rid="article-24291.r34">[34]</xref></p>
        <p><bold>Hyponatremia:</bold> Monitoring serum sodium levels regularly for patients at risk of hyponatremia or syndrome of inappropriate diuretic hormone (SIADH) is essential.<xref ref-type="bibr" rid="article-24291.r35">[35]</xref><xref ref-type="bibr" rid="article-24291.r36">[36]</xref></p>
        <p><bold>Phenylketonuria:</bold> Use caution when prescribing linezolid oral suspension to patients with phenylketonuria (PKU) due to the presence of phenylalanine. Other linezolid formulations do not contain phenylalanine.<xref ref-type="bibr" rid="article-24291.r37">[37]</xref></p>
      </sec>
      <sec id="article-24291.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring parameters include heart rate, blood pressure, blood glucose, weekly complete blood count (CBC), and fundus examination. Blood pressure requires close monitoring in patients with untreated hyperthyroidism. Patients with disease-related concerns such as diabetes mellitus, hypertension, hyperthyroidism, pheochromocytoma, and carcinoid syndrome also&#x000a0;require close monitoring.<xref ref-type="bibr" rid="article-24291.r37">[37]</xref></p>
      </sec>
      <sec id="article-24291.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity is infrequent, and no antidote for linezolid is currently available. Symptomatic and supportive treatment is recommended for managing mild to severe toxicity. For severe neutropenia, administer colony-stimulating factors such as filgrastim or sargramostim. Filgrastim is dosed at 5 mcg/kg/day subcutaneous (SQ) or IV over 15 to 30 minutes, or sargramostim at 250 mcg/m<sup>2</sup>/day IV over 4 hours. Transfusion of platelets, packed red cells, or both may be necessary for patients with severe thrombocytopenia, anemia, or hemorrhage.</p>
        <p>For seizures, administer IV benzodiazepines; barbiturates or propofol may be an option if seizures persist or recur. Airway management may be necessary for patients with severe seizures. The primary treatment for serotonin syndrome is sedation with IV benzodiazepines and cooling measures (cyproheptadine is an option for milder cases). Start with an initial dose of 12 mg of cyproheptadine, followed by 2 mg every 2 hours if symptoms persist.&#x000a0;When stability is attained, switch to a maintenance dose of 8 mg every 6 hours. Ensure that the daily dose for adults does not surpass 0.5 mg/kg/day.<xref ref-type="bibr" rid="article-24291.r38">[38]</xref>&#x000a0;Activated charcoal is a consideration in patients with a recent overdose of linezolid tablets and co-ingested potentially dangerous medications, eg, tricyclic antidepressants.</p>
        <p>Monitoring is necessary for vital signs and liver enzymes in symptomatic patients. Additionally, monitor serial CBC with differential and platelet count. Reports exist of myelosuppression, including anemia, pancytopenia, leukopenia, and thrombocytopenia in patients receiving linezolid. Monitoring serum electrolyte status is indicated for patients with significant diarrhea and vomiting.</p>
      </sec>
      <sec id="article-24291.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The healthcare team&#x000a0;should&#x000a0;work together to ensure the patient receives linezolid correctly and is monitored for adverse drug reactions. Educate the patient on the signs of significant adverse drug reactions such as wheezing, chest tightness, seizures, swelling of the face, lips, tongue, or throat, and severe diarrhea. Encourage the patient to consult the&#x000a0;treating clinician for questions about linezolid treatment. To prevent the inappropriate clinical use of linezolid, most hospitals have a committee that includes a pharmacist and an infectious disease expert who&#x000a0;should authorize&#x000a0;the&#x000a0;prescription.</p>
        <p>A study evaluated the impact of interventions by an antimicrobial stewardship team (AST) involving the pharmacy, microbiology, and infectious diseases departments on linezolid utilization. Using defined daily doses (DDD) per 1,000 inhabitants per day as a metric, the study found that 60% of linezolid prescriptions were considered appropriate. Inappropriate treatments were modified or discontinued in 62% and 38% of cases. The mean duration of linezolid treatment was&#x000a0;8 days, below the national average. Interprofessional teams developed a consensual approach for treating ventilator-acquired pneumonia. Importantly, the mean DDD per 1,000 inhabitants per day showed a gradual and favorable reduction throughout the study, highlighting the positive impact of the team's actions in optimizing linezolid use.&#x000a0;IDSA also suggests that&#x000a0;clinicians coordinate for effective antimicrobial stewardship.<xref ref-type="bibr" rid="article-24291.r39">[39]</xref><xref ref-type="bibr" rid="article-24291.r40">[40]</xref><xref ref-type="bibr" rid="article-24291.r39">[39]</xref></p>
      </sec>
      <sec id="article-24291.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24291">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24291/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24291">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24291.s11">
        <title>References</title>
        <ref id="article-24291.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narayanan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhowmick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia.</article-title>
            <source>Ther Adv Infect Dis</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>6</volume>
            <fpage>2049936119828964</fpage>
            <pub-id pub-id-type="pmid">30792858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Linezolid: a review of its use in the management of serious gram-positive infections.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-51</page-range>
            <pub-id pub-id-type="pmid">11324682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thakuria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agwan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>GC07</fpage>
            <page-range>GC07-GC11</page-range>
            <pub-id pub-id-type="pmid">28969155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalil</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Klompas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muscedere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El Solh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ewig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fey</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Cruse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>e61</fpage>
            <page-range>e61-e111</page-range>
            <pub-id pub-id-type="pmid">27418577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metlay</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Musher</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Whitney</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>200</volume>
            <issue>7</issue>
            <fpage>e45</fpage>
            <page-range>e45-e67</page-range>
            <pub-id pub-id-type="pmid">31573350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bidaisee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18925</fpage>
            <pub-id pub-id-type="pmid">34812309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bisno</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hirschmann</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Jul</month>
            <day>15</day>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-59</page-range>
            <pub-id pub-id-type="pmid">24947530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendricks</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shadomy</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Holty</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Messonnier</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Pesik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Treadwell</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <collab>Workgroup on Anthrax Clinical Guidelines</collab>
            </person-group>
            <article-title>Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">24447897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Stapert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moerman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Linezolid, critical characteristics.</article-title>
            <source>Infection</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-4</page-range>
            <pub-id pub-id-type="pmid">10697798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dresser</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.</article-title>
            <source>Pharmacotherapy</source>
            <year>1998</year>
            <season>May-Jun</season>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>456</fpage>
            <page-range>456-62</page-range>
            <pub-id pub-id-type="pmid">9620097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diekema</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Oxazolidinones: a review.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">10718097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antal</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hendershot</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Batts</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2001</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-62</page-range>
            <pub-id pub-id-type="pmid">11361052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brade</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wichelhaus</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>1570</fpage>
            <page-range>1570-2</page-range>
            <pub-id pub-id-type="pmid">18212098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norrby</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Linezolid--a review of the first oxazolidinone.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-302</page-range>
            <pub-id pub-id-type="pmid">11336587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Linezolid as salvage therapy for central nervous system infections due to methicillin-resistant Staphylococcus aureus at two medical centers in Taiwan.</article-title>
            <source>J Microbiol Immunol Infect</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>909</fpage>
            <page-range>909-915</page-range>
            <pub-id pub-id-type="pmid">32859532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Heinrichs</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Nikolaishvili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sabulua</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bablishvili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gogishvili</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avaliani</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Bernheim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Derendorf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blumberg</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vashakidze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.</article-title>
            <source>Eur Respir J</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29437945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dryden</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2011</year>
            <month>May</month>
            <volume>66 Suppl 4</volume>
            <fpage>iv7</fpage>
            <page-range>iv7-iv15</page-range>
            <pub-id pub-id-type="pmid">21521707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luque</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz-Bermudez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Echeverr&#x000ed;a-Esnal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sorli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Campillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Casanova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Colominas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Lerma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Horcajada</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Grau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity.</article-title>
            <source>Ther Drug Monit</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>732</fpage>
            <page-range>732-739</page-range>
            <pub-id pub-id-type="pmid">31259884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crass</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Cojutti</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pea</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">31109977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Linezolid</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>9</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bookstaver</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stover</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Eiland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Review of Antibiotic Use in Pregnancy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1052</fpage>
            <page-range>1052-62</page-range>
            <pub-id pub-id-type="pmid">26598097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alene</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>van de Water</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Becerra</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Atalell</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Nicol</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>ACA</given-names>
              </name>
            </person-group>
            <article-title>Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>e2216527</fpage>
            <pub-id pub-id-type="pmid">35687333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Linezolid.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>815</fpage>
            <page-range>815-27; discussion 828</page-range>
            <pub-id pub-id-type="pmid">10804037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chien</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kucia</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Salata</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>146</fpage>
            <page-range>146-51</page-range>
            <pub-id pub-id-type="pmid">10619743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gortney</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists.</article-title>
            <source>Pharmacotherapy</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1784</fpage>
            <page-range>1784-93</page-range>
            <pub-id pub-id-type="pmid">17125439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantarini</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Painter</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gilmore</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral linezolid on the pressor response to intravenous tyramine.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>470</fpage>
            <page-range>470-5</page-range>
            <pub-id pub-id-type="pmid">15521893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stroup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Som</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Linezolid-induced serotonin toxicity in a patient not taking monoamine oxidase inhibitors or serotonin receptor antagonists.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-5</page-range>
            <pub-id pub-id-type="pmid">27034576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2017</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2017</volume>
            <issue>1</issue>
            <fpage>187</fpage>
            <page-range>187-193</page-range>
            <pub-id pub-id-type="pmid">29222255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Syal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tahlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Reversible Myelosuppresion With Prolonged Usage of Linezolid in Treatment of Methicillin-Resistant Staphylococcus aureus.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Oct</month>
            <day>10</day>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>e10890</fpage>
            <pub-id pub-id-type="pmid">33194459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grever</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Abdel-Wahab</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Andritsos</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barrientos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blachly</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Call</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Catovsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dearden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Else</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gozzetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juliusson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kraut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kreitman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Larratt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lozanski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montserrat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Polliack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quest</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Ravandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Robak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tadmor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tiacci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Troussard</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zent</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Zenz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Falini</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Feb</month>
            <day>02</day>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>553</fpage>
            <page-range>553-560</page-range>
            <pub-id pub-id-type="pmid">27903528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dilley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>463</fpage>
            <page-range>463-475</page-range>
            <pub-id pub-id-type="pmid">34910281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haworth</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Capstick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gorsuch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laurenson</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Leitch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loebinger</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Milburn</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Nightingale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ormerod</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shingadia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Floto</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).</article-title>
            <source>Thorax</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>Suppl 2</issue>
            <fpage>ii1</fpage>
            <page-range>ii1-ii64</page-range>
            <pub-id pub-id-type="pmid">29054853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>McClelland</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Linezolid optic neuropathy.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <page-range>481-486</page-range>
            <pub-id pub-id-type="pmid">37603423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elbarbry</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moshirian</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Linezolid-associated serotonin toxicity: a systematic review.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>7</issue>
            <fpage>875</fpage>
            <page-range>875-883</page-range>
            <pub-id pub-id-type="pmid">37129603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stavroulaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mavrikaki</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Papakitsou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Panagiotakis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A case of severe hyponatremia due to linezolid-induced SIADH.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>434</fpage>
            <page-range>434-436</page-range>
            <pub-id pub-id-type="pmid">29542179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>QW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A case of linezolid-induced SIADH in elderly and a review of the literature.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>16</issue>
            <fpage>5706</fpage>
            <page-range>5706-5709</page-range>
            <pub-id pub-id-type="pmid">36066143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garazzino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tovo</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience with linezolid in infants and children.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2011</year>
            <month>May</month>
            <volume>66 Suppl 4</volume>
            <fpage>iv23</fpage>
            <page-range>iv23-iv41</page-range>
            <pub-id pub-id-type="pmid">21521704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Vashistha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houchens</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: Preventing, recognizing, and treating it.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>83</volume>
            <issue>11</issue>
            <fpage>810</fpage>
            <page-range>810-817</page-range>
            <pub-id pub-id-type="pmid">27824534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de La Blanchardi&#x000e8;re</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cattoir</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Verdon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saint-Lorant</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial stewardship and linezolid.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1059</fpage>
            <page-range>1059-68</page-range>
            <pub-id pub-id-type="pmid">25135806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24291.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barlam</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Abbo</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>MacDougall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuetz</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Septimus</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellit</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Lipsett</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Neuhauser</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ohl</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>May</month>
            <day>15</day>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>e51</fpage>
            <page-range>e51-77</page-range>
            <pub-id pub-id-type="pmid">27080992</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
